Your browser doesn't support javascript.
loading
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy.
Luttwak, Efrat; Smith, Mitchell R; Zelenetz, Andrew D.
Affiliation
  • Luttwak E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Smith MR; The Follicular Lymphoma Foundation, Washington, USA.
  • Zelenetz AD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Expert Opin Pharmacother ; 24(12): 1331-1334, 2023.
Article in En | MEDLINE | ID: mdl-37294016
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, B-Cell / Antineoplastic Agents Limits: Humans Language: En Journal: Expert Opin Pharmacother Journal subject: FARMACOLOGIA Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, B-Cell / Antineoplastic Agents Limits: Humans Language: En Journal: Expert Opin Pharmacother Journal subject: FARMACOLOGIA Year: 2023 Document type: Article Affiliation country: Country of publication: